HOLON, Israel, April 26, 2017 /PRNewswire/ --
Compugen Ltd. (NASDAQ: CGEN), a
therapeutic discovery company, announced today that the Company
will host a live conference call on Tuesday,
May 9, 2017 at 10:00 AM ET to
review first quarter 2017 results. Compugen participants on the
conference call will include Martin
Gerstel, Chairman; Dr. Anat
Cohen-Dayag, President and Chief Executive Officer; and
Ari Krashin, Chief Financial and
Operating Officer. The quarterly results will be released on the
Company's website (http://www.cgen.com) prior to the call.
To access the live conference call by telephone, please dial
1-888-281-1167 from the US,
or +972-3-918-0644 internationally. The call will also be available
via live webcast through Compugen's website, located at the
following link. Following the live audio webcast, a replay will be
available on the Company's website through June 9, 2017.
About Compugen
Compugen is a leading therapeutic discovery company whose
mission is to utilize its broadly applicable predictive discovery
infrastructure to discover novel drug targets and develop
first-in-class therapeutics. Our current pipeline consists of early
and preclinical stage immuno-oncology programs based on novel drug
targets discovered internally, primarily immune checkpoint and
myeloid protein target candidates. These programs focus on the
development of first-in-class cancer immunotherapy drugs with the
potential to harness the immune system to provide treatment
solutions in areas of unmet medical need in various cancer types
and patient populations, both as monotherapy and in combination
with other drugs. In addition, our pipeline currently includes a
preclinical fusion protein autoimmune product candidate. Compugen's
business model is based on selectively entering into collaborations
for its novel target candidates and related drug product candidates
at various stages of research and development under revenue-sharing
agreements. The Company is headquartered in Israel, with R&D facilities in
Israel and South San Francisco. At
the US facilities, therapeutic monoclonal antibodies are discovered
and developed against the Company's novel drug target
candidates.
For additional information, please visit Compugen's corporate
website at http://www.cgen.com.
Company contact:
Susanna Chau
Director, Investor Relations and Corporate Communications
Compugen
Email: susannac@cgen.com
Tel: +1 (650) 263-7001
SOURCE Compugen Ltd.